The companies aim to develop the respiratory syncytial virus
challenge strain in order to help advance progress towards a
universal vaccine against the virus, SGS said in a statement on
RSV is a significant cause of respiratory illness in all agegroups,
and is the most common cause of lower respiratorytract infections in
children worldwide, resulting in a high number of hospitalizations.
SGS cited WHO estimates which said RSV infects more than 64 million
people globally each year and causes a similar number of deaths to
those caused by influenza.
(Reporting by Brenna Hughes Neghaiwi, editing by John Revill)
[© 2017 Thomson Reuters. All rights
Copyright 2017 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.